Clinical Development & Regulatory Consulting in India

Moving a drug from preclinical work into human trials, and from one clinical phase to the next, turns on decisions made before any application is filed: whether the program is ready to enter humans, what the next study must establish, which Indian pathway applies, and whether the data being generated will support the milestone after this one.

EvySaif provides sponsor-side clinical development and regulatory consulting in India for pharmaceutical companies, biotechnology companies and drug developers running new drug programs. The work covers Phase I, II and III strategy, CDSCO clinical trial submissions, clinical documentation, regulatory responses and India strategy for global development programs. Each engagement starts from three questions: where the program stands, what it needs next, and what could stop it reaching the next milestone.

What a clinical development consultant does

A clinical development consultant supports the decisions around the program, before and during the trials. A clinical trial consultancy or contract research organization (CRO) works mainly on the study itself: site selection, monitoring, recruitment, data management, trial operations. The trial-level question is how a Phase II study should be conducted; the development-level question is whether this is the right Phase II study to generate the evidence Phase III needs. EvySaif works at the development level and alongside a CRO where full trial operations are required.

Depending on the stage, the work includes preclinical-to-clinical readiness assessment, first-in-human strategy, Phase I to III planning, clinical trial regulatory strategy, CDSCO submission preparation and responses, protocol and Investigator's Brochure development, clinical evidence assessment, India strategy for global programs, development gap and risk assessment, and marketing authorization readiness. Programs supported include small molecules, biologics and biosimilars, phytopharmaceuticals, and clinical studies of nutraceutical products.

The most useful moment for external input is before the next major milestone. EvySaif assesses a program across six areas and grades each finding Ready, Gap or Risk, with a recommended action. The output is a gap list with owners and priorities, produced before the gaps surface as protocol amendments or regulatory queries.

• Drug candidate with no human data: preclinical-to-Phase I readiness assessment.
• Planning first-in-human development: Phase I strategy and regulatory support.
• Phase I completed: Phase II development planning.
• Planning Phase II: proof-of-concept, dose and evidence strategy.
• Phase II completed: Phase III readiness assessment.
• Preparing Phase III: confirmatory development and registration strategy.
• Global clinical program: India regulatory and development strategy.
• Preparing an Indian clinical trial: CDSCO pathway confirmation and application support.
• Regulatory query received: scientific and regulatory response support.
• Clinical development completed: marketing authorization readiness assessment.

Phase I carries the program from nonclinical work into humans, establishing initial safety, tolerability and pharmacokinetics, with pharmacodynamic measures where relevant. Before a Phase I submission, EvySaif assesses the readiness of the whole package: the nonclinical evidence behind the proposed exposure, the dose rationale and escalation design, the study population, the protocol, the investigational product information, the Investigator's Brochure and the consent documents, together with the CDSCO and ethics committee requirements around them.

For molecules developed outside India, CDSCO addresses when overseas Phase I results support proceeding in India without repeating the phase, and the assessment settles that position before the application is drafted. The application itself is prepared once the whole package is confirmed ready for the proposed study.

Phase II establishes whether the drug shows clinical activity in the target disease and which dose and strategy go forward. The decisions carrying the most weight are proof-of-concept design, dose selection, patient population, endpoints, comparator, safety monitoring, the pharmacokinetic and pharmacodynamic relationships, the statistical approach, and the pre-defined criteria for progressing to Phase III.

EvySaif supports these through development strategy work, protocol development and review, evidence assessment, dose and endpoint strategy, CDSCO and ethics committee submissions, and a Phase II-to-Phase III readiness assessment once the data are in. The design work starts from the questions the Phase III decision depends on.

Phase III generates the confirmatory efficacy and safety evidence for the intended indication, and by this stage the program needs a settled position on indication, population, dose and regimen, primary and secondary endpoints, comparator, safety requirements, statistics, and the registration objective the trial serves. EvySaif reviews the Phase II evidence against the proposed Phase III design, runs the evidence-gap assessment, and connects the trial design to the eventual marketing application. Where the registration will lean on the trial for an Indian approval, the design choices the Subject Expert Committee weighs (population relevance, comparator against Indian standard of care, dose justification) are addressed at protocol stage.

Clinical trials of new drugs and investigational new drugs in India run under the New Drugs and Clinical Trials Rules 2019. The forms, review clocks, ethics committee requirements and waiver provisions are explained in our CDSCO new drug approval guide. EvySaif's support covers:

CDSCO announced parallel submission and processing of clinical trial applications by CDSCO and registered ethics committees in May 2026, so submission sequencing is now part of the filing plan.

Development programs run on documents that must be scientifically accurate, internally consistent and written for their audience. EvySaif prepares and reviews clinical trial protocols, Investigator's Brochures, Informed Consent Forms, clinical summaries, regulatory briefing documents, application supporting documents, responses to regulatory queries, Clinical Study Reports and periodic safety documentation. Each document is written to communicate why the study is being run, what the evidence shows, what the study will establish and how the approach is justified, and the set is checked for consistency across documents before anything is filed.

For a global sponsor, the question is how India fits the established program: whether Indian sites join a global Phase II or III trial, whether the global protocol works for the Indian population and ethics committees, and what India-specific gaps exist in the package. EvySaif assesses the global clinical data, the current phase, the protocol, the investigational product information, the existing approvals and the Indian requirements, and returns the changes an Indian arm needs. CDSCO's FAQ states that the applicant for a clinical trial or BA/BE study of a new drug or investigational new drug must have a permanent establishment in India, so the applicant entity is settled before anything else is planned.

For smaller biotechnology companies, the same work substitutes for functions the company has not yet built: readiness for first-in-human development, what CDSCO will expect, how Phase I data shape Phase II, whether the Phase II package can carry Phase III, and how a global program takes on an Indian arm.

What this engagement does not replace

EvySaif's consulting is sponsor-side strategy, regulatory work and documentation. It does not replace clinical site operations, patient recruitment, routine monitoring, site management, trial logistics, data management operations or clinical laboratory services. Where those are needed, they sit with a CRO or specialist operational partner, and EvySaif works alongside them. The split lets the sponsor keep development strategy and regulatory decision-making separate from trial operations.

• Program assessment. Product, indication, current stage, available evidence and the intended next milestone.
• Regulatory and development review. The applicable Indian pathway and the requirements of the proposed stage.
• Gap and risk assessment. Nonclinical, clinical, CMC, documentation and submission readiness, graded with actions.
• Development plan. The regulatory, clinical and documentation activities, prioritized against the milestone.
• Document development. Preparation or review of the agreed documents.
• Regulatory support. CDSCO interactions, submissions and responses through the review.
• Next-milestone reassessment. The strategy revisited as new evidence lands, before the next commitment.

What you receive

Each engagement closes with named deliverables: the Clinical Development Readiness Report (the six areas graded Ready, Gap or Risk, with a prioritized action list), an India development and regulatory roadmap for the agreed milestone, the authored or reviewed documents in submission-ready form, and, where the scope includes regulatory interactions, the briefing book and the query response package.

An unsuitable development sequence, a missing nonclinical study, an unclear pathway or a protocol problem found at assessment stage is corrected in the plan; found after the study has run, it can mean repeating the study. The assessment states the requirements, the evidence position and the risks before the next development commitment; approval decisions rest with CDSCO. For the market-entry and lifecycle strategy around the development program, our regulatory strategy consulting and CDSCO India submission services carry the work through registration.

EvySaif is a clinician-led clinical development and regulatory consultancy. The consulting is directed by Dr Idris Dawaiwala, a clinical pharmacologist in active tertiary-care hospital practice in Pune, with peer-reviewed publications including first-author pharmaceutical research. The wider team covers regulatory writing, biostatistics-literate clinical review, health economics and medical affairs, and the firm works with pharmaceutical, biotech and device clients across India, the Middle East and Europe. The people who assess the evidence are the people who write the documents and prepare the regulatory answers.